TSE:4503Pharmaceuticals
Astellas Pharma (TSE:4503) Margin Surge To 13.6% Tests Bearish Earnings Narratives
Astellas Pharma (TSE:4503) has laid out its FY 2026 scorecard with second half revenue of ¥1.1t and basic EPS of ¥80.33, alongside net income excluding extraordinary items of ¥143.9b. The company has seen revenue move from ¥976.7b and basic EPS of ¥12.72 in the second half of FY 2025, to ¥1.0t and ¥82.44 in the first half of FY 2026, before reaching ¥1.1t and ¥80.33 in the latest period. Over the same timeframe, trailing twelve month EPS has increased from ¥28.35 to ¥162.77. For investors,...